SG11201806122YA - Proteinaceous compounds and uses therefor - Google Patents
Proteinaceous compounds and uses thereforInfo
- Publication number
- SG11201806122YA SG11201806122YA SG11201806122YA SG11201806122YA SG11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA SG 11201806122Y A SG11201806122Y A SG 11201806122YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- pkc
- english
- february
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11013—Protein kinase C (2.7.11.13)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 10 August 2017 (10.08.2017) WIPO I PCT (10) International Publication Number WO 2017/132728 Al 11111111111110110111111111110101111101111111011101011110111011111111111111111 (51) International Patent Classification: A61K 38/17 (2006.01) A61P 35/00 (2006.01) A61K 38/43 (2006.01) (21) International Application Number: PCT/AU2017/050083 (22) International Filing Date: 1 February 2017 (01.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016900314 1 February 2016 (01.02.2016) AU (71) Applicant: UNIVERSITY OF CANBERRA [AU/AU]; University Drive, Bruce, Australian Capital Territory 2617 (AU). (72) Inventors: RAO, Sudha; 102 Buxton Street, Deakin, Aus- tralian Capital Territory 2600 (AU). MILBURN, Peter; 8 Miller Street, O'Connor, Australian Capital Territory 2602 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; Level 10, 301 Coronation Drive, Milton, Queensland 4064 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) W O 20 17 / 13 27 28 Al (54) Title: PROTEINACEOUS COMPOUNDS AND USES THEREFOR (57) : Disclosed are proteinaceous molecules and their use in conditions associated with PKC-0 overexpression, such as cancer. More particularly, the present invention discloses proteinaceous molecules and their use in altering at least one of (i) forma - tion; (ii) proliferation; (iii) maintenance; (iv) epithelial to mesenchymal cell transition; or (v) mesenchymal to epithelial cell trans - ition of a PKC-0 overexpressing cell.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900314A AU2016900314A0 (en) | 2016-02-01 | Proteinaceous compounds and uses therefor | |
| PCT/AU2017/050083 WO2017132728A1 (en) | 2016-02-01 | 2017-02-01 | Proteinaceous compounds and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806122YA true SG11201806122YA (en) | 2018-08-30 |
Family
ID=59499146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806122YA SG11201806122YA (en) | 2016-02-01 | 2017-02-01 | Proteinaceous compounds and uses therefor |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10487115B2 (en) |
| EP (1) | EP3411061A4 (en) |
| JP (2) | JP7341451B2 (en) |
| CN (2) | CN108883155A (en) |
| AU (1) | AU2017214761B2 (en) |
| CA (1) | CA3011870A1 (en) |
| SG (1) | SG11201806122YA (en) |
| WO (1) | WO2017132728A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111587120A (en) * | 2017-11-08 | 2020-08-25 | 艾比克斯治疗私人有限公司 | Immunogenic compositions and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament having an antiangiogenic and/or vascular permeability reducing effect |
| WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| AUPP807899A0 (en) | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
| WO2000036083A2 (en) | 1998-12-17 | 2000-06-22 | La Jolla Institute For Allergy And Immunology | Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| RU2003103603A (en) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Derivatives of colchinol as inhibitors of angiogenesis |
| WO2002010193A1 (en) * | 2000-07-31 | 2002-02-07 | Dabur Research Foundation | Lipid-peptide conjugates for treatment of cancer |
| AU2003236720A1 (en) | 2002-06-14 | 2003-12-31 | Altana Pharma Ag | Substituted diaminopyrimidines |
| WO2004076654A1 (en) * | 2003-02-28 | 2004-09-10 | Novartis Ag | Three-dimensional structure of the catalytic domain of protein c theta, methods and use thereof |
| WO2005115444A2 (en) | 2004-04-14 | 2005-12-08 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
| JP5295785B2 (en) | 2006-02-20 | 2013-09-18 | エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション | Cell membrane permeable peptide |
| WO2012058715A1 (en) * | 2010-11-01 | 2012-05-10 | University Of Technology, Sydney | Immune-modulating agents and uses therefor |
| ES2679995T3 (en) * | 2011-03-11 | 2018-09-03 | Vib Vzw | Molecules and methods for protein inhibition and detection |
| CN112225819A (en) | 2012-09-27 | 2021-01-15 | 不列颠哥伦比亚大学 | Peptide-directed protein knockdown |
| ES2851724T3 (en) * | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Stem cell modulation |
| CA2958704A1 (en) | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
-
2017
- 2017-02-01 JP JP2018539984A patent/JP7341451B2/en active Active
- 2017-02-01 SG SG11201806122YA patent/SG11201806122YA/en unknown
- 2017-02-01 CN CN201780021694.9A patent/CN108883155A/en active Pending
- 2017-02-01 EP EP17746642.2A patent/EP3411061A4/en active Pending
- 2017-02-01 CN CN202211550292.7A patent/CN116082457A/en active Pending
- 2017-02-01 CA CA3011870A patent/CA3011870A1/en not_active Abandoned
- 2017-02-01 WO PCT/AU2017/050083 patent/WO2017132728A1/en active Application Filing
- 2017-02-01 US US16/074,690 patent/US10487115B2/en active Active
- 2017-02-01 AU AU2017214761A patent/AU2017214761B2/en active Active
-
2021
- 2021-10-29 JP JP2021178010A patent/JP2022023949A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108883155A (en) | 2018-11-23 |
| JP7341451B2 (en) | 2023-09-11 |
| AU2017214761B2 (en) | 2024-02-01 |
| CA3011870A1 (en) | 2017-08-10 |
| EP3411061A4 (en) | 2019-07-10 |
| JP2019506167A (en) | 2019-03-07 |
| WO2017132728A1 (en) | 2017-08-10 |
| JP2022023949A (en) | 2022-02-08 |
| AU2017214761A1 (en) | 2018-08-02 |
| CN116082457A (en) | 2023-05-09 |
| US20190040103A1 (en) | 2019-02-07 |
| US10487115B2 (en) | 2019-11-26 |
| EP3411061A1 (en) | 2018-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901624RA (en) | Lysine specific histone demethylase-1 inhibitors and uses therefor | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201900743UA (en) | Multiple function exercise device | |
| SG11201407774XA (en) | Conversion of biomass | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201901172QA (en) | A method for manufacturing a fuel component | |
| SG11201810975UA (en) | Method for stabilizing proteins | |
| SG11201805191SA (en) | Yeast cell | |
| SG11201803762RA (en) | High viscosity base stock compositions | |
| SG11201909872WA (en) | Stability of short path evaporation treated oils | |
| SG11201406927VA (en) | Electrolytic cell equipped with concentric electrode pairs |